Pukhalsky A L, Toptygina A P, Viktorov V V
Institute of Medical Genetics, Moscow, U.S.S.R.
Int J Immunopharmacol. 1990;12(2):217-23. doi: 10.1016/0192-0561(90)90056-s.
Determination of the amount of alkylating (NBP) metabolites of cyclophosphamide (CP) in blood serum of BALB/c and DBA/2 mice has revealed that the shape of the curve describing the accumulation of NBP-metabolites, depends on the administered drug dose and animals' genotype. The experimental data obtained made it possible to suggest an improved pharmacokinetic model which takes into account a possible switching in of factors conditioning non-linear changes in the intensity of the accumulation processes in blood and elimination of CP alkylating metabolites from blood. The effect of different CP alkylating metabolite kinetics in BALB/c and DBA/2 mice on a different sensitivity of these mice to the immunodepressive action of CP in vivo, has been discussed.
对BALB/c和DBA/2小鼠血清中环磷酰胺（CP）的烷基化（NBP）代谢物含量的测定表明，描述NBP代谢物积累的曲线形状取决于给药剂量和动物基因型。所获得的实验数据使得有可能提出一种改进的药代动力学模型，该模型考虑到了可能影响血液中积累过程强度非线性变化的因素以及CP烷基化代谢物从血液中消除的情况。讨论了BALB/c和DBA/2小鼠中不同的CP烷基化代谢物动力学对这些小鼠在体内对CP免疫抑制作用不同敏感性的影响。
